Factors associated with neutropenia post heart transplantation

被引:5
作者
Chow, Jennifer K. L. [1 ]
Ruthazer, Robin [2 ]
Boucher, Helen W. [1 ]
Vest, Amanda R. [3 ]
DeNofrio, David M. [3 ]
Snydman, David R. [1 ]
机构
[1] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA
[2] Tufts Med Ctr, Biostat Epidemiol & Res Design Ctr, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA
[3] Tufts Univ, Tufts Med Ctr, Sch Med, Div Cardiol, Boston, MA 02111 USA
关键词
CMV; heart transplant; infection; neutropenia; ANTIBODY-MEDIATED REJECTION; PATHOLOGICAL DIAGNOSIS; KIDNEY-TRANSPLANTATION; MYCOPHENOLATE-MOFETIL; WORKING FORMULATION; PREEMPTIVE THERAPY; CLINICAL IMPACT; RISK-FACTORS; CYTOMEGALOVIRUS; PROPHYLAXIS;
D O I
10.1111/tid.13634
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Neutropenia is a serious complication following heart transplantation (OHT); however, risk factors for its development and its association with outcomes is not well described. We sought to study the prevalence of neutropenia, risk factors associated with its development, and its impact on infection, rejection, and survival. Methods A retrospective single-center analysis of adult OHT recipients from July 2004 to December 2017 was performed. Demographic, laboratory, medication, infection, rejection, and survival data were collected for 1 year post-OHT. Baseline laboratory measurements were collected within the 24 hours before OHT. Neutropenia was defined as absolute neutrophil count <= 1000 cells/mm3. Cox proportional hazards models explored associations with time to first neutropenia. Associations between neutropenia, analyzed as a time-dependent covariate, with secondary outcomes of time to infection, rejection, or death were also examined. Results Of 278 OHT recipients, 84 (30%) developed neutropenia at a median of 142 days (range 81-228) after transplant. Factors independently associated with increased risk of neutropenia included lower baseline WBC (HR 1.12; 95% CI 1.11-1.24), pre-OHT ventricular assist device (1.63; 1.00-2.66), high-risk CMV serostatus [donor positive, recipient negative] (1.86; 1.19-2.88), and having a previous CMV infection (4.07; 3.92-13.7). Conclusions Neutropenia is a fairly common occurrence after adult OHT. CMV infection was associated with subsequent neutropenia, however, no statistically significant differences in outcomes were found between neutropenic and non-neutropenic patients in this small study. It remains to be determined in future studies if medication changes in response to neutropenia would impact patient outcomes.
引用
收藏
页数:9
相关论文
共 30 条
  • [11] The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients
    George, MJ
    Snydman, DR
    Werner, BG
    Griffith, J
    Falagas, ME
    Dougherty, NN
    Rubin, RH
    [J]. AMERICAN JOURNAL OF MEDICINE, 1997, 103 (02) : 106 - 113
  • [12] Ho S, 2020, J HEART LUNG TRANSPL, V39, pS503
  • [13] Poor Outcomes Associated With Neutropenia After Kidney Transplantation: Analysis of United States Renal Data System
    Hurst, Frank P.
    Belur, Pallavi
    Nee, Robert
    Agodoa, Lawrence Y.
    Patel, Purav
    Abbott, Kevin C.
    Jindal, Rahul M.
    [J]. TRANSPLANTATION, 2011, 92 (01) : 36 - 40
  • [14] Cellular immunity impaired among patients on left ventricular assist device for 6 months
    Kimball, Pam M.
    Flattery, Maureen
    McDougan, Felecia
    Kasirajan, Vigneshwar
    [J]. ANNALS OF THORACIC SURGERY, 2008, 85 (05) : 1656 - 1661
  • [15] Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
    Knoll, GA
    MacDonald, I
    Khan, A
    Van Walraven, C
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09): : 2381 - 2386
  • [16] The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
    Kotton, Camille N.
    Kumar, Deepali
    Caliendo, Angela M.
    Huprikar, Shirish
    Chou, Sunwen
    Danziger-Isakov, Lara
    Humar, Atul
    [J]. TRANSPLANTATION, 2018, 102 (06) : 900 - 931
  • [17] Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials
    Ljungman, Per
    Boeckh, Michael
    Hirsch, Hans H.
    Josephson, Filip
    Lundgren, Jens
    Nichols, Garrett
    Pikis, Andreas
    Razonable, Raymund R.
    Miller, Veronica
    Griffiths, Paul D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 64 (01) : 87 - 91
  • [18] Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients
    Martin-Gandul, Cecilia
    Perez-Romero, Pilar
    Gonzalez-Roncero, Francisco M.
    Berdaguer, Soledad
    Gomez, Miguel A.
    Lage, Ernesto
    Sanchez, Magdalena
    Cisneros, Jose M.
    Cordero, Elisa
    [J]. JOURNAL OF INFECTION, 2014, 69 (05) : 500 - 506
  • [19] Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
    Marty, F. M.
    Ljungman, P.
    Chemaly, R. F.
    Maertens, J.
    Dadwal, S. S.
    Duarte, R. F.
    Haider, S.
    Ullmann, A. J.
    Katayama, Y.
    Brown, J.
    Mullane, K. M.
    Boeckh, M.
    Blumberg, E. A.
    Einsele, H.
    Snydman, D. R.
    Kanda, Y.
    DiNubile, M. J.
    Teal, V. L.
    Wan, H.
    Murata, Y.
    Kartsonis, N. A.
    Leavitt, R. Y.
    Badshah, C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25) : 2433 - 2444
  • [20] Neutropenia in kidney and liver transplant recipients: Risk factors and outcomes
    Mavrakanas, Thomas A.
    Fournier, Marie-Andree
    Clairoux, Sarah
    Amiel, Jacques-Alexandre
    Tremblay, Marie-Eve
    Vinh, Donald C.
    Coursol, Christian
    Thirion, Daniel J. G.
    Cantarovich, Marcelo
    [J]. CLINICAL TRANSPLANTATION, 2017, 31 (10)